Fixed-dose combination of amlodipine/indapamide/perindopril arginine — a rational and safe choice for blood pressure control in actual clinical setting: data of an observational program DOKAZATEL`STVO

• Published in: Rossiĭskiĭ kardiologicheskiĭ zhurnal Vol. 25; no. 6; p. 3805
• Main Authors: Kobalava, J. D., Tolkacheva, V. V., Troitskaya, E. A., Kolesnikova, I. A., Markova, M. A.
• Format: Journal Article
• Language: English; Russian
• Published: FIRMA «SILICEA» LLC 11.07.2020
• Subjects: amlodipine/indapamide/perindopril arginine; fixed-dose combination; hypertension; triple antihypertensive therapy; triplixam
• ISSN: 1560-4071; 2618-7620
• DOI: 10.15829/1560-4071-2020-3805

Aim . To analyze the efficacy and tolerability of amlodipine/indapamide/perindopril arginine (Triplixam) in a subgroup of 790 people participating in the Russian observational program DOKAZATEL`STVO without use of other antihypertensive agents. Material and methods . The analysis included 790 patients with hypertension (HTN) (men — 37,9%, mean age — 60,0±10,2 years). The drug was administrated in one of 4 recommended dosages for 3 months. We assessed the dynamics of office and home blood pressure (BP) from visit 1 to visit 4 and the frequency of achieving the target BP <140/90 mm Hg in 3 months. Results . After 3 months, office systolic BP (SBP) decreased from 163,4±14,0 to 127,2±7,8 mm Hg, diastolic BP (DBP) — from 95,7±9,5 to 78,3±6,2 mm Hg (p 0,001). Home SBP in the morning decreased from 145,9±12,3 to 128,3±7,8 mm Hg, DBP — from 86,2±7,7 to 78,4±5,6 mm Hg (p<0,001). After 3 months, target office BP (<140/90 mm Hg) was achieved in 88,4% of subjects, home BP (<135/85 mm Hg) — 73%. Conclusion . The administration of Triplixam without additional antihypertensive agents results in a significant BP decrease by 36/17 mm Hg and rapid achievement of BP control in most patients. The combination is safe and well tolerated.